Ignite Creation Date:
2024-05-05 @ 5:25 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00443170
Status:
COMPLETED
Last Update Posted:
2012-03-19
First Post:
2007-03-01
Brief Title:
A Placebo-controlled Study to Investigate the Safety and Pharmacokinetics of Oral GSK626616AC in Healthy Subjects
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Randomized Blinded Placebo-controlled Study to Investigate the Safety and Pharmacokinetics of Single and Repeat Dose Escalation of the Oral YAK3DYRK3 Inhibitor GSK626616AC in Healthy Subjects
Status:
COMPLETED
Status Verified Date:
2011-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a first time in human study to investigate the safety of GSK626616AC given as oral single and repeat doses in healthy subjects An additional group of subjects will be assessed to determine the effect of several drugs given at the same time as GSK626616
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None